Vestipitant

Drug Profile

Vestipitant

Alternative Names: 597599; GW 597599; GW 597599B

Latest Information Update: 31 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antidepressants; Antiemetics; Anxiolytics; Mesylates; Piperazines; Small molecules
  • Mechanism of Action Neurokinin 1 antagonists; Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Dyspepsia; Hearing loss; Major depressive disorder; Postoperative nausea and vomiting; Tinnitus

Most Recent Events

  • 29 Feb 2012 Phase-II clinical trials in Postoperative nausea and vomiting in USA (IV)
  • 21 May 2007 No development reported - Phase-II for Postoperative nausea and vomiting in USA (unspecified route)
  • 25 Nov 2005 Data presented at the 18th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2005) have been added to the adverse events , pharmacokinetics and Anxiety disorders pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top